our program

Targeting the shared driver of Thyroid Eye Disease and Graves’ Disease

our program

Targeting the shared driver of Thyroid Eye Disease and Graves’ Disease

ETHY-001: Precision Targeting of TSHR

ETHY-001: Precision Targeting of TSHR

ETHY-001 is designed to block the activation of TSHR by stimulating autoantibodies (TSAbs).

In the orbit of the eye, this approach is expected to treat the signs and symptoms of TED. In thyroid cells, this same approach is predicted to treat GD by reducing excess thyroid hormone production.

ETHY-001 has the potential to be a single, precise, and comprehensive treatment for both TED and GD.

ETHY-001 is designed to block the activation of TSHR by stimulating autoantibodies (TSAbs).

In the orbit of the eye, this approach is expected to treat the signs and symptoms of TED. In thyroid cells, this same approach is predicted to treat GD by reducing excess thyroid hormone production.

ETHY-001 has the potential to be a single, precise, and comprehensive treatment for both TED and GD.

ETHY-001

ETHY-001

Potential best-in-class treatment for both TED & GD

Potential best-in-class treatment for both TED & GD

Engineered for rapid onset and robust efficacy across the full spectrum of TED & GD

Engineered for rapid onset and robust efficacy across the full spectrum of TED & GD

Safety profile supports long-term treatment and durable disease control

Safety profile supports long-term treatment and durable disease control

Patient-friendly infrequent subcutaneous administration (autoinjector)

Patient-friendly infrequent subcutaneous administration (autoinjector)